Establishment of a High-throughput Setup for Screening Small Molecules That Modulate c-di-GMP Signaling in Pseudomonas aeruginosa

Overview

This article describes a high-throughput assay developed to screen small molecules for their ability to manipulate cyclic di-GMP levels in Pseudomonas aeruginosa. This method provides a robust tool for antibacterial drug discovery and compound testing.

Key Study Components

Area of Science

• Microbiology
• Pharmacology
• Antibacterial drug discovery

Background

• Cyclic di-GMP is a second messenger involved in biofilm formation in Pseudomonas aeruginosa.
• Modulating its levels can influence bacterial behavior and antibiotic susceptibility.
• High-throughput screening allows for rapid testing of large compound libraries.
• This study aims to identify small molecules that can effectively alter cyclic di-GMP levels.

Purpose of Study

• To establish a high-throughput bio-reporter screen for identifying small molecules.
• To uncover compounds that interfere with Pseudomonas aeruginosa bioinformation.
• To develop potential therapies that enhance bacterial sensitivity to the immune system or antibiotics.

Methods Used

• Preparation of electro-competent Pseudomonas aeruginosa cells.
• Electroporation of plasmids encoding GFP under the control of the CdrA promoter.
• High-throughput screening of small molecules in 384-well plates.
• Measurement of optical density and fluorescence to assess compound effects.

Main Results

• Successful identification of small molecules that modulate cyclic di-GMP levels.
• Demonstrated robustness of the screening method with over 3,500 compounds tested in 48 hours.
• Potential for developing new antibacterial therapies based on identified compounds.

Conclusions

• The high-throughput assay is a powerful tool for drug discovery.
• Identified compounds may lead to novel treatments for infections caused by Pseudomonas aeruginosa.
• This approach can be adapted for screening other pathogens and compounds.

Frequently Asked Questions